Breaking News Instant updates and real-time market news.

CGC

Canopy Growth

$19.42

-1.005 (-4.92%)

, STZ

Constellation Brands

$193.15

0.47 (0.24%)

07:19
10/14/19
10/14
07:19
10/14/19
07:19

Canopy, Hexo downgraded to Neutral as Seaport Global cuts cannabis estimates

Seaport Global analyst Brett Hundley lowered his sales and earnings forecasts for the conventional Canadian cannabis companies he covers as part of a broader reset of expectations for the Canadian cannabis space. As part of the broader changes, he downgraded Canopy Growth (CGC) and Hexo Corp. (HEXO), both to Neutral from Buy. Hundley has lowered his FY21 view for Canopy's revenue to $475.5M and his EBITDA forecast to ($75.1M), adding that he no longer feels confident in the company's potential to receive incremental equity warrant funding from Constellation (STZ) in the near-term. For Hexo, he now sees FY21 revenue of $121.7M and $0.2M in EBITDA. He expects market pricing to become "considerably more challenged" as industry production funnels into "a limited store set" in Canada, Hundley tells investors. He keeps a Buy rating on Aphria (APHA), making it his only Buy-rated conventional Canadian cannabis company, though he cut his price target on the stock to $8 from $13. Hundley has Neutral ratings on Aurora Cannabis (ACB) and Tilray (TLRY).

CGC

Canopy Growth

$19.42

-1.005 (-4.92%)

STZ

Constellation Brands

$193.15

0.47 (0.24%)

STZ.B

Constellation Brands; also tag STZ

$190.14

(0.00%)

HEXO

Hexo

$2.54

-0.295 (-10.42%)

APHA

Aphria

$4.71

0.085 (1.84%)

ACB

Aurora Cannabis

$3.68

-0.045 (-1.21%)

TLRY

Tilray

$20.97

0.34 (1.65%)

  • 15

    Oct

  • 29

    Oct

  • 12

    Nov

  • 12

    Nov

CGC Canopy Growth
$19.42

-1.005 (-4.92%)

10/11/19
JEFF
10/11/19
DOWNGRADE
Target $18.8
JEFF
Underperform
Jefferies downgrades Canopy to Underperform, calls most expensive in cannabis
Jefferies analyst Owen Bennett downgraded Canopy Growth to Underperform from Hold with a price target of $18.80. The stock closed Thursday down $2.37 to $20.42. Despite the recent selloff in shares, Canopy is the most expensive name across the cannabis space, Bennett tells investors in a research note. The analyst, who believes the company still has "material potential" long-term, says signs of share pressures in Canada, weak margin and profit performance in the near term, a lack of material catalysts, and "question marks over how successful beverages will be" warrant a downgrade to Underperform.
10/11/19
10/11/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Crowdstrike (CRWD) downgraded to Sell from Neutral at Goldman Sachs with analyst Heather Bellini stating while CrowdStrike is very well positioned in the market for endpoint security, a "blue sky analysis" suggests this is likely priced in at current share levels. 2. Terex (TEX) downgraded to Underweight from Equal Weight at Barclays with analyst Adam Seiden expecting the rental equipment market to move from equilibrium to oversupplied by 2020. 3. Delta Air Lines (DAL) downgraded to Hold from Buy at Argus with analyst John Staszark saying that while Delta is among the best managed airlines, he thinks better returns are available elsewhere, as Delta is facing prospects for rising costs and slowing revenue growth. 4. PG&E (PCG) downgraded to Sell from Neutral at Citi with analyst Praful Mehta seeing a 75% chance of the stock going to zero after Judge Montali terminated PG&E's exclusive right to advance a plan of reorganization. 5. Canopy Growth (CGC) downgraded to Underperform from Hold at Jefferies with analyst Owen Bennett saying despite the recent selloff in shares, Canopy is the most expensive name across the cannabis space. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/14/19
GHSC
10/14/19
DOWNGRADE
GHSC
Neutral
Canopy Growth downgraded to Neutral from Buy at Seaport Global
10/11/19
JEFF
10/11/19
UPGRADE
JEFF
Hold
Jefferies upgrades Hexo to Hold, says pressures now understood
Jefferies analyst Owen Bennett upgraded Hexo (HEXO) to Hold from Underperform with a price target of $2.90. The pressures facing the company are now better understood following its weaker than expected outlook, Bennett tells investors in a research note. The analyst this morning also downgraded Canopy Growth (CGC) to Underperform from Hold. His top picks Cannabis are Aurora Cannabis (ACB), Aphria (APHA) and Green Organic Dutchman (TGODF).
STZ Constellation Brands
$193.15

0.47 (0.24%)

10/07/19
ARGS
10/07/19
NO CHANGE
Target $230
ARGS
Buy
Constellation Brands price target raised to $230 from $220 at Argus
Argus analyst John Staszak raised his price target on Constellation Brands to $230 and kept his Buy rating after its Q2 earnings beat, also keeping his FY20 and FY21 EPS views at $9.10 and $10.30. The analyst is positive on the company's recent additions to its brand portfolio, with increased focus on the U.S. beer market and higher than expected operating margin, noting that Constellation Brands should continue to benefit from economies of scale. Staszak adds that while the multiple of 21.4-times his expected earnings is above the company's 10-year historical average of 18 and the average of 17 for other growing Consumer Staples companies, it is warranted by the company's prospects for above average growth.
10/04/19
MKMP
10/04/19
NO CHANGE
Target $256
MKMP
Buy
Constellation Brands price target lowered to $256 from $263 at MKM Partners
MKM Partners analyst Bill Kirk lowered his price target on Constellation Brands to $256 after its Q2 results, saying that while beer net sales grew 7.4%, the worse than expected Wine/Spirits revenue and EBIT weighed on the revenue and prevented a stronger earnings beat. The analyst is keeping his Buy rating on the stock and expects the company's Beer business to offset any Wine issues, but also believes that the management pulled the spending around the departing brands "too quickly".
10/04/19
FBCO
10/04/19
NO CHANGE
Target $228
FBCO
Outperform
Constellation Brands price target loweredt o $228 from $230 at Credit Suisse
Credit Suisse analyst Kaumil Gajrawala lowered his price target for Constellation Brands to $228 from $230, telling investors that distractions aside, Constellation reported its largest quarter mostly in line with or slightly above estimates. Gajrawala says in a research note that he sees an opportunity to own on the pullback and reiterated an Outperform rating.
09/27/19
09/27/19
UPGRADE

Positive
Constellation Brands upgraded to Positive following checks at OTR Global
As previously reported, OTR Global upgraded Constellation Brands to Positive from Mixed. The firm's checks indicate Q2 beer volumes are up 8%-11%, versus up 4%-7% in Q1, with positive feedback on sales of Corona Refresca and Corona Premier.
STZ.B Constellation Brands; also tag STZ
$190.14

(0.00%)

07/03/19
STFL
07/03/19
NO CHANGE
STFL
Buy
Linton's vision to be 'sorely missed' at Canopy, says Stifel
Stifel analyst W. Andrew Carter maintained a Buy rating on Canopy Growth (CGC) after the company announced a "surprising" change in leadership, with founder and co-CEO Bruce Linton stepping down from his roles, Mark Zekulin stepping in as CEO, and the board searching for a permanent successor at CEO. Carter believes the board is "is likely unsatisfied with the company's operational performance in recent periods and sees a change in leadership as necessary to right the ship" but also believes Linton's vision and founder status will be "sorely missed." The analyst also noted that Constellation Brands (STZ), Canopy's largest investor, now has four of six total board seats, and had previously stated that it was not pleased with Canopy's recent performance, supporting "Canopy on a more focused long-term strategy to win markets and form factors that matter."
07/15/19
BOFA
07/15/19
DOWNGRADE
Target $50
BOFA
Underperform
BofA/Merrill double downgrades Molson Coors to Underperform
As previously reported, BofA Merrill Lynch analyst Bryan Spillane downgraded Molson Coors (TAP) two notches, to Underperform from Buy, citing the heightened potential he sees that the company will need to increase spending to stabilize core brands' market share and invest in premium and "beyond" beer segments. To support his view, Spillane notes that Molson Coors has continued to lose market share in FY19 as competitors such as AB InBev (BUD), Heineken (HEINY), Constellation (STZ) and Boston Beer (SAM) have increased marketing/brand support and that products like hard seltzers and canned wine pose further risk to domestic light beer. He lowered his price target on Molson Coors shares to $50 from $70.
09/19/19
MKMP
09/19/19
INITIATION
Target $263
MKMP
Buy
Constellation Brands initiated with a Buy at MKM Partners
MKM Partners analyst Bill Kirk initiated Constellation Brands with a Buy rating and $263 price target.
09/20/19
MKMP
09/20/19
INITIATION
Target $263
MKMP
Buy
MKM Partners starts Constellation at Buy on Modelo's 'unrelenting strength'
As previously reported, MKM Partners analyst Bill Kirk initiated Constellation Brands (STZ) with a Buy rating and $263 price target, telling investors that Modelo's "unrelenting strength" and cash generation affords the company flexibility to invest in innovation, adjacent industries and marketing while Most of its peers face declining volumes and P&L pressures. Modelo has become, or nearly is, the biggest brand in some major regions of the U.S. and Kirk believes this trend will continue, he said.
HEXO Hexo
$2.54

-0.295 (-10.42%)

10/11/19
10/11/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Workday (WDAY) upgraded to Buy from Neutral at Goldman Sachs with analyst Heather Bellini saying recent partner checks suggest accelerating momentum in the company's cloud based financial migrations. 2. Perrigo (PRGO) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg stating that given his expectation that the company will begin to show initial results from its consumer-focused transition later in the year, shares appear attractively valued at 13.1-times his 2019 EPS estimates. 3. Square (SQ) upgraded to Positive from Neutral at Susquehanna with analyst James Friedman noting the stock's underperformance was due to valuation, decelerating margin expansion and decelerating GPV growth and saying he sees the company's return on margin reinvestment on the horizon. 4. Hexo (HEXO) upgraded to Hold from Underperform at Jefferies with analyst Owen Bennett stating the pressures facing the company are now better understood following its weaker than expected outlook. 5. USA Technologies (USAT) upgraded to Buy from Hold at Lake Street with analyst Jaeson Schmidt saying the company's filing of audited financials earlier this week, while containing a lot of moving parts, is a net positive. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/19
ROTH
10/11/19
DOWNGRADE
Target $3
ROTH
Neutral
Roth Capital downgrades Hexo to Neutral after guidance pulled
As previously reported, Roth Capital analyst Scott Fortune downgraded Hexo to Neutral from Buy with a price target of $3.00, down from $10.00, after the company pre-announced weak Q4 revenue and withdrew its 2020 outlook. Hexo, which Fortune contends "has always had a good pulse on the political and regulatory environment for cannabis in Canada," called out the legal cannabis industry's issues there and the analyst said legal access to the Canadian cannabis market remains materially underserved, which he does not see changing in the near-term. As of May, Canada's planned or operating retail locations are "about 90% short of matching the store density of a state such as Colorado," Fortune added in his downgrade note.
10/14/19
GHSC
10/14/19
DOWNGRADE
GHSC
Neutral
Hexo downgraded to Neutral from Buy at Seaport Global
APHA Aphria
$4.71

0.085 (1.84%)

10/10/19
STFL
10/10/19
NO CHANGE
STFL
Hexo miss further damages cannabis industry credibility, says Stifel
Hexo (HEXO) this morning provided a preliminary update for its fiscal Q4 with revenue coming in below the consensus estimate and well below the "double" offered by management mid-quarter during the Q3 earnings call, Stifel analyst Andrew Carter tells investors in a research note. The preannouncement is "another headline damaging" the cannabis industry's credibility, Carter tells investors in a research note. For companies facing "significant financing risk," the analyst believes a "real segregation of assets will occur." Some companies will face significant dilution due to onerous financing terms while others will simply be unable to access capital, predicts the analyst. Carter thinks the macro environment will continue to be difficult and that the capital positions of Canopy Growth (CGC) and Cronos Group (CRON) are "clear competitive advantages." Those two have the ability to continue executing their business plans while capitalizing on the sector weakness, which "will only intensify from here," says Carter. Other names in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY) and Zynerba (ZYNE). Shares of Hexo are down 24%, or 90c, to $2.78 in early trading.
10/09/19
ROTH
10/09/19
NO CHANGE
ROTH
Roth says low enthusiasm for cannabis stocks doesn't reflect industry potential
Roth Capital analyst Scott Fortune noted that stocks in the cannabis sector have declined during the six months since the first quarter with the industry "mired in a capital crunch, with a vape crisis to make matters worse." However, he thinks the recently lower enthusiasm for cannabis stocks does not reflect the cannabis industry's prospects, as he still sees a lot of upside potential. A "meaningful shift" in investor focus to operational execution has led to a short-term correction in valuations, but the industry is still projected to grow at a 27% compound annual growth rate for the next three years, said Fortune, who advises that investors focus for now on companies with strong balance sheets and positive adjusted EBITDA who are nearing break even. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), Tilray (TLRY), and Trulieve Cannabis (TCNNF).
09/26/19
COMP
09/26/19
NO CHANGE
COMP
Cannabis banking bill should find path to passage in Senate, says Compass Point
After the House of Representatives cleared the SAFE Banking Act by a vote of 321 to 103, Compass Point analyst Isaac Boltansky said the bipartisan clearance of the cannabis banking bill should be viewed as a tailwind for the bill's prospects in the Senate and he continue to think it will find "a path to passage" as part of a broader legislative package. He thinks that the SAFE Act will expand access to banking services for legal cannabis operators, but cautions that any immediate expansion is likely to be modest. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY), and Trulieve Cannabis (TCNNF).
ACB Aurora Cannabis
$3.68

-0.045 (-1.21%)

10/07/19
BOFA
10/07/19
NO CHANGE
BOFA
Cannabis consensus estimates still may be 30% too high, says BofA/Merrill
BofA Merrill Lynch analyst Christopher Carey thinks that valuations across the cannabis sector are looking more reasonable following the selloff since April, though he still believes consensus estimates for the group are likely at least 30% too high. Given this view, he is of the opinion that the true "buy" signal for the sector won't come until sales estimates are significantly recalibrated. Though individual companies could gain share, on an industry level, sales estimates are too high, contends Carey, who thinks the stocks in the group could remain volatile for some time. He prefers Cronos Group (CRON), which he thinks stands out "as an especially attractive buying opportunity" following the group's pullback, Carey tells investors. He keeps a Buy rating on Cronos, has Neutral ratings on Aurora Cannabis (ACB) and Canopy Growth (CGC) and maintains an Underperform rating on HEXO Corp (HEXO).
TLRY Tilray
$20.97

0.34 (1.65%)

09/20/19
MKMP
09/20/19
INITIATION
MKMP
Neutral
MKM Partners starts Tilray at Neutral, says consensus too high
As previously reported, MKM Partners analyst Bill Kirk initiated Tilray with a Neutral rating and $34 price target. While he likes the company's strategy in terms of entering the U.S. via hemp seed food products and cultivating in Portugal to service European markets, he also thinks FY20 consensus estimates are still too high. He also thinks profitability for Canadian cultivation will get worse before it gets better, as he believes flower and production for extraction will get commoditized.

TODAY'S FREE FLY STORIES

MASI

Masimo

$156.34

-1.11 (-0.70%)

12:05
12/05/19
12/05
12:05
12/05/19
12:05
Conference/Events
Masimo management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

ACHN

Achillion

$6.16

-0.025 (-0.40%)

12:05
12/05/19
12/05
12:05
12/05/19
12:05
Options
Achillion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 19

    Dec

TVTY

Tivity Health

$22.60

-0.23 (-1.01%)

12:04
12/05/19
12/05
12:04
12/05/19
12:04
Conference/Events
Tivity Health management to meet with Piper Jaffray »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

MIC

Macquarie Infrastructure

$42.49

0.43 (1.02%)

12:04
12/05/19
12/05
12:04
12/05/19
12:04
Conference/Events
Macquarie Infrastructure management to meet with Suntrust »

Group Dinner with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

TCBK

TriCo Bancshares

$38.57

0.09 (0.23%)

12:03
12/05/19
12/05
12:03
12/05/19
12:03
Conference/Events
TriCo Bancshares management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 11

    Dec

FB

Facebook

$198.74

0.04 (0.02%)

, NKE

Nike

$94.84

1.12 (1.20%)

12:02
12/05/19
12/05
12:02
12/05/19
12:02
On The Fly
Fly Intel: Wall Street's top stories at midday »

After two volatile days…

FB

Facebook

$198.74

0.04 (0.02%)

NKE

Nike

$94.84

1.12 (1.20%)

AAPL

Apple

$263.99

2.21 (0.84%)

WORK

Slack Technologies

$22.30

0.61 (2.81%)

VRNT

Verint

$52.36

4.54 (9.49%)

AUPH

Aurinia Pharmaceuticals

$16.22

7.84 (93.56%)

SIG

Signet Jewelers

$18.21

1.56 (9.37%)

SPWH

Sportsman's Warehouse

$8.03

0.67 (9.10%)

SAGE

Sage Therapeutics

$63.20

-86.02 (-57.65%)

HOME

At Home Group

$5.61

-2.94 (-34.39%)

ESTC

Elastic

$65.45

-12.98 (-16.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 09

    Dec

  • 16

    Dec

  • 19

    Dec

PK

Park Hotels & Resorts

$23.53

-0.09 (-0.38%)

12:02
12/05/19
12/05
12:02
12/05/19
12:02
Conference/Events
Park Hotels & Resorts management to meet with Suntrust »

Hotel Property Tour with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

BRY

Berry Petroleum

$8.35

0.23 (2.83%)

12:02
12/05/19
12/05
12:02
12/05/19
12:02
Conference/Events
Berry Petroleum management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

BAH

Booz Allen

$72.59

0.26 (0.36%)

, AMZN

Amazon.com

$1,745.65

-15.55 (-0.88%)

12:01
12/05/19
12/05
12:01
12/05/19
12:01
Hot Stocks
Booz Allen says has capabilities to support AWS Outposts »

Booz Allen Hamilton (BAH)…

BAH

Booz Allen

$72.59

0.26 (0.36%)

AMZN

Amazon.com

$1,745.65

-15.55 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOV

Hovnanian

$24.49

3.15 (14.76%)

12:00
12/05/19
12/05
12:00
12/05/19
12:00
Hot Stocks
Hovnanian rises 14.2% »

Hovnanian is up 14.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

AZZ

AZZ Inc.

$44.00

5.63 (14.67%)

12:00
12/05/19
12/05
12:00
12/05/19
12:00
Hot Stocks
AZZ Inc. rises 14.4% »

AZZ Inc. is up 14.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

EXPR

Express

$4.74

0.845 (21.72%)

12:00
12/05/19
12/05
12:00
12/05/19
12:00
Hot Stocks
Express rises 21.1% »

Express is up 21.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

CSIQ

Canadian Solar

$18.04

0.6 (3.44%)

, FSLR

First Solar

$53.47

-1.33 (-2.43%)

11:57
12/05/19
12/05
11:57
12/05/19
11:57
Periodicals
U.S. trade court grants injunction in solar tariff dispute, Bloomberg says »

The U.S. Court of…

CSIQ

Canadian Solar

$18.04

0.6 (3.44%)

FSLR

First Solar

$53.47

-1.33 (-2.43%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.25

-0.12 (-1.63%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$124.40

-0.02 (-0.02%)

11:57
12/05/19
12/05
11:57
12/05/19
11:57
Periodicals
Target to open Times Square store in NY in 2022, CNBC says »

Lauren Thomas of CNBC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$149.81

-0.04 (-0.03%)

11:55
12/05/19
12/05
11:55
12/05/19
11:55
Periodicals
Microsoft 365 consumer subscription to be revealed in spring 2020, ZDNet says »

Microsoft originally…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

11:55
12/05/19
12/05
11:55
12/05/19
11:55
General news
Treasury's $75 B 4- and 8-week bill auctions were very well received »

Treasury's $75 B 4-…

11:55
12/05/19
12/05
11:55
12/05/19
11:55
Conference/Events
William Blair aerospace & defense analyst to hold a group luncheon »

Aerospace & Defense…

11:55
12/05/19
12/05
11:55
12/05/19
11:55
Conference/Events
William Blair commercial services analyst to hold luncheon meeting »

Commercial Services…

AMZN

Amazon.com

$1,746.32

-14.88 (-0.84%)

, MSFT

Microsoft

$149.74

-0.11 (-0.07%)

11:52
12/05/19
12/05
11:52
12/05/19
11:52
Periodicals
Imgur launches gaming clips app Melee to rival Twitch, Verge says »

Photo-sharing site Imgur…

AMZN

Amazon.com

$1,746.32

-14.88 (-0.84%)

MSFT

Microsoft

$149.74

-0.11 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

BIIB

Biogen

$286.74

-2.61 (-0.90%)

11:49
12/05/19
12/05
11:49
12/05/19
11:49
Hot Stocks
Biogen reverses, moves up as CTAD presentation ends, panel Q&A session begins »

Shares of Biogen have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

AUPH

Aurinia Pharmaceuticals

$15.83

7.45 (88.90%)

11:49
12/05/19
12/05
11:49
12/05/19
11:49
Recommendations
Aurinia Pharmaceuticals analyst commentary  »

Aurinia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

KMI

Kinder Morgan

$19.45

0.15 (0.78%)

11:45
12/05/19
12/05
11:45
12/05/19
11:45
Options
Kinder Morgan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNSS

Sunesis

$0.24

-0.1499 (-38.45%)

11:44
12/05/19
12/05
11:44
12/05/19
11:44
Hot Stocks
Sunesis announces data from ongoing Phase 1b/2 trial of vecabrutinib »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

BIIB

Biogen

$286.74

-2.61 (-0.90%)

11:39
12/05/19
12/05
11:39
12/05/19
11:39
Hot Stocks
Biogen down 3% as trading resumes, medical conference presentation continues »

Biogen representatives…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

SAGE

Sage Therapeutics

$63.85

-85.37 (-57.21%)

11:38
12/05/19
12/05
11:38
12/05/19
11:38
Recommendations
Sage Therapeutics analyst commentary  »

Sage Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.